Smith Group Asset Management LLC Makes New $1.62 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

Smith Group Asset Management LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,224 shares of the medical research company’s stock, valued at approximately $1,616,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. FMR LLC raised its position in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of IQVIA in the third quarter worth $147,683,000. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Nordea Investment Management AB increased its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, KBC Group NV raised its stake in IQVIA by 68.5% in the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after purchasing an additional 250,458 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 1.6 %

Shares of IQVIA stock opened at $203.59 on Wednesday. The company has a fifty day moving average price of $200.02 and a 200 day moving average price of $221.09. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock has a market cap of $36.95 billion, a price-to-earnings ratio of 26.72, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. TD Cowen lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft dropped their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Truist Financial decreased their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.